Research-Meningococcal Vaccine Efficacy

General Information
Program/Project Name: Evaluation of Meningococcal Conjugate Vaccine and Other High-Priority Vaccine Preventable Diseases

Funding Category: Serving the Most Vulnerable

Program Description
Federal Grant Name: American Recovery and Reinvestment Act (ARRA)-Strengthening the Evidence Base Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Evaluation of Meningococcal Conjugate Vaccine and Other High-Priority Vaccine Preventable Diseases

Programs Supported Through Funding: Immunization Research, Division of Disease Control, Department of Public Health

Amount Applied For: $125,288

Fund Awarded: $125,288

Why Apply for this Grant?
The prevention and control of vaccine preventable diseases is a priority for the Philadelphia Department of Public Health (PDPH).  Invasive meningococcal disease, pertussis, and invasive Haemophilus influenzae serotype b infections (Hib) are three conditions that cause significant morbidity and mortality among young children and adolescents in Philadelphia, and warrant enhanced surveillance efforts and evaluation of vaccine effectiveness.

Program Objectives: The objectives of this project are to enhance laboratory and epidemiologic surveillance for meningococcal disease and evaluate the effectiveness of meningococcal conjugate vaccine using a case-control approach; to improve surveillance for invasive Hi infections among children < 5 years old to assess the impact of Hib vaccine shortages; and to improve and expedite recognition of outbreaks of pertussis, and communicate them to the Centers for Disease Control and Prevention (CDC), so that they serve as opportunities to assess pertussis diagnostics and vaccine effectiveness.

Grant Achievements for the Quarter: For this reporting quarter, the Health Department’s Division of Disease Control (DDC) has; (1) developed a health care provider in-service on disease reporting and surveillance, with emphasis on testing methods and reporting of vaccine preventable diseases, 12 in-services conducted; (2) continued development of laboratory guidance for health care providers that details specimen collection methods and testing procedures for vaccine preventable diseases; and (3) performed trend analyses for meningococcal disease, pertussis, and invasive Haemophilus influenzae infection in Philadelphia. No current cases of meningococcal meningitis have met the case definition for enrollment in the MCV4 vaccine effectiveness study. DDC continues to participate on bimonthly conference calls with CDC and other grant recipients.

Actual # of FTE jobs created for the quarter*:

Q8: 1.33

Q9: 1.10

Q10: 1.41

*In the City of Philadelphia’s quarterly federal report, also know as Section 1512 reports, jobs are calculated based on hours worked, instead of the number of people at work. It also looks only at jobs funded directly by the Recovery Act, and does not include jobs created indirectly. Direct jobs are counted quarterly and are not cumulative.

This entry was posted in Meningococcal Vaccine Efficacy, Research. Bookmark the permalink.